SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment

SIRPα antibody combined with oncolytic virus OH2 protects against tumours by activating innate immunity and reprogramming the tumour immune microenvironment

Abstract Background The combination of oncolytic viruses (OVs) with immune checkpoint blockades is a research hotspot and has shown good efficacy. Here, we present the first attempt to combine oncolytic herpes simplex virus 2 (OH2) with an anti-SIRPα antibody as an antitumour treatment. Our results...

Full description

Bibliographic Details
Main Authors: Defeng Kong, Zhenrong Yang, Guoliang Li, Quanyou Wu, Zhaoru Gu, Duo Wan, Qi Zhang, Xiaoli Zhang, Shujun Cheng, Binlei Liu, Kaitai Zhang, Wen Zhang
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Medicine
Subjects:
Oncolytic virus
Oncolytic herpes simplex virus 2
SIRPα
Macrophage
Tumour microenvironment environment
Online Access:https://doi.org/10.1186/s12916-022-02574-z

Internet

https://doi.org/10.1186/s12916-022-02574-z

Similar Items